Neurolymphomatosis—diagnosis and assessment of treatment response by FDG PET‐CT
Authors:
Open Access
- 24 October 2007
- journal article
- case report
- Published by Wiley in Hematological Oncology
- Vol. 26 (1) , 43-45
Abstract
Neurolymphomatosis (NL) is lymphomatous infiltration of peripheral nerves, and is an uncommon manifestation of non‐Hodgkin's lymphoma (NHL). Although nerve biopsy is the main method for histological diagnosis, a blind nerve biopsy may not be diagnostic. While CT and MRI have been used to detect NL, recent reports demonstrated the benefit of integrated positron emission tomography (PET) using F18‐2‐fluoro‐2‐deoxy‐D‐glucose (FDG) combined with computed tomography (CT). We described the utility of FDG PET‐CT in this uncommon subgroup of NHL where it can assist in establishing the diagnosis, the potential to guide sites for biopsy and in the assessment of response to therapy. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 8 references indexed in Scilit:
- Diagnosis of neurolymphomatosis with FDG PETNeurology, 2006
- FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphomaAnnals of Oncology, 2005
- A metaanalysis of 18F‐2‐deoxy‐2‐fluoro‐D‐glucose positron emission tomography in the staging and restaging of patients with lymphomaCancer, 2005
- PET‐CT imaging of combined brachial and lumbosacral neurolymphomatosisEuropean Journal of Haematology, 2004
- Predictive role of positron emission tomography (PET) in the outcome of lymphoma patientsBritish Journal of Cancer, 2004
- NeurolymphomatosisNeuro-Oncology, 2003
- Negative sural nerve biopsy in neurolymphomatosisJournal of Neurology, 1999
- Effects of Lymphoma on the Peripheral Nervous SystemJournal of the Royal Society of Medicine, 1994